Loading
A phase 2 trial of Atezolizumab in small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07654400 by Sichuan Baili Pharmaceutical Co., Ltd., with 36 participants planned, started 2026-07-09 and due to reach its primary completion in 2027-12. Interventions recorded: BL-M14D1, Atezolizumab. Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SystImmune / Sichuan Biokin, Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares SystImmune / Sichuan Biokin, Extensive-stage small-cell lung cancer, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares SystImmune / Sichuan Biokin, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/